
A drug which can extend the lives of some men with prostate cancer will not be approved for use on the NHS.
In final guidance which rubber-stamps an earlier decision, the National Institute for Health and Care Excellence (Nice) said olaparib (also called Lynparza) is not a good use of NHS money at its current price.